Fetal Bovine Serum for Biochemistry Section (BCS) Cell Culture Research
Department of Health and Human Services, National Institutes of Health | Published April 19, 2017 - Deadline April 28, 2017
Fetal Bovine Serum for Biochemistry Section (BCS) Cell Culture Research
Pre-Solicitation Notice of Intent to Sole Source
INTRODUCTIONThis is a combined synopsis/pre-solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. This acquisition is being conducted in accordance with the procedures of FAR Part 13--Simplified Acquisition Procedures and FAR Part 12--Acquisition of Commercial Items.
The solicitation number is HHS-NIH-NIDA-SSSA-NOI-17-268 and the solicitation is issued as a PRE-SOLICITATION, NOTICE OF INTENT, to award a contract on a noncompetitive basis to Sigma-Aldrich, Inc 3050 Spruce St Saint Louis MO 63103.
REGULATORY & STATUTORY AUTHORITYThis acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13--Simplified Acquisition Procedures, Subpart 13.106-1, only one responsible source and no other supplies or services will satisfy agency requirements, and FAR Part 12--Acquisition of Commercial Items and is NOT expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13--Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6--Competition Requirements.
The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-95, dated January 19, 2017.
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODEThe associated NAICS code for this requirement is 325199 with size standard of 1,250 employees.
CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATIONThe non-competitive determination is based upon the market research conducted as prescribed in FAR Part 10--Market Research, which indicates that only Sigma-Aldrich, Inc can fulfill the necessary requirement. Specifically, Sigma-Aldrich is the sole source provider of the Fetal Bovine Serum and does not authorized anyone to distribute this material nor can it be obtained through a reseller. For these many reasons and to ensure continuity of scientific research data, Sigma-Aldrich Inc is the only contractor capable of meeting the needs of this requirement.
This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
DESCRIPTION OF REQUIREMENT
BackgroundThe Biochemistry Section (BCS) is a cell biology laboratory that uses HeLa, HCT116, M7, SH-SY5Y, U2OS, 293T cells to study apoptosis, mitochondria dynamics and Pink1/Parkin-mediated mitophagy over the last 20 years. BCS staff require cell lines daily to study fundamental questions regarding Parkinson's disease, cancer and other neurodegenerative diseases. FBS is required to maintain the basic research for better understanding human diseases.
Purpose and ObjectivesThe purpose of this acquisition is to procure Fetal Bovine Serum (FBS) used in mammalian cell lines for cell culture research. Due to the nature of FBS production, the quality varies from lot to lot, company to company; hence it is extremely important to secure a large amount of FBS from the same lot to maintain consistency of cell growth and performance, which is the key for generating reproducible data.
Project DescriptionGeneric Name of Product: Fetal Bovine SerumTrade name: Sigma-Aldrich Fetal Bovine SerumProduct's brand name: Sigma-Aldrich Fetal Bovine Serum Manufacturer's name: Sigma-AldrichModel, type, catalog, and/or part number(s): Material Number #F8317-500 ml, Batch Number #16G420Salient characteristics The Contractor shall provide the NINDS Biochemistry Section, 200 bottles of Sigma-Aldrich fetal bovine [Sigma-Aldrich Material Number F8317-500 ml, Batch Number 16G420] serum that meets the following characteristics: Serum must have no visible cell death or slowing growth during at last one month of culture time. Transfection efficiency should not be less than the current serum Gemini Biologicals, Cat# 100-106, Lot# A03D00E) being used. Serum must have mitophagy induction below 5% with oligomycin and Antimycin A (OAQ) treatment for 24 hours. Serum must have, at a minimum, 90% or more green fluorescent protein (GFP) intensity and GFP-positive cells. Quantity: 200 bottles of Fetal Bovine Serum in 500 ml bottle
Non-Personal Service Statement:In accordance with FAR 37.104, this requirement is for non-personal services and does not include any inherently governmental functions; functions that are closely associated with inherently governmental functions; unauthorized personal services; critical and/or core functions.
Period of PerformanceContractor shall deliver 200 bottles of fetal bovine serum. Government shall, in writing or via email, notify Contactor to deliver 50 bottles of fetal bovine serum at a time. Contractor shall deliver within 1 week of notification. Bottles shall be delivered to 35 Convent Drive, Building 35, Room 2C915. Office-site storage shall be provided until all 200 bottles are delivered.
Place of Performance: The place of performance shall be the NIH Main Campus, 35 Covent Drive, Building 35, Room 2C915 Bethesda, MD 20892.
Contract TypeA Firm Fixed Price Purchase Order is contemplated. The order shall be sourced via the Open Market on a single-source basis and is not expected to exceed $150,000.
RESPONSE INSTRUCTIONSResponses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. Offerors must provide both 1) a technical response and 2) a separate price quote. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; and maintenance availability.
PLEASE ENSURE THAT ALL EVALUATION CRITERIA ARE SPECIFICALLY ADDRESSED IN ANY RESPONSE(S) SUBMITTED.
EVALUATION CRITERIAFAR clause 52.212-2, Evaluation - Commercial Items (October 2014) applies to this acquisition and the specific evaluation criteria to be included in paragraph (a) of that provision are as follows:
The Government will award a contract resulting from this requirement on the basis of best value, technical factors and price considered. Technical factors together shall be considered more important than price and all technical evaluation factors are detailed below.
Factor 1: Supply Capability The contractor shall detail in its technical proposal how it shall meet each of the project requirements. This shall include detailed specifications of the offered serum and its capabilities. Technical approach shall be evaluated for the ways in which the proposed serum meets or exceeds the serum specification requirements. Exceeding requirements shall be considered favorably.
Factor 2: Delivery and StorageThe contractor shall detail in its technical proposal how it shall meet the delivery, and storage requirements. The Government shall evaluate for ability to meet or exceed these requirements. Proposals must include a delivery lead-time and transportation and off-site contractor storage.
Factor 3: Past PerformanceThe Contractor shall provide a list of three (3) contracts or purchase orders completed during the past five (5) years, similar in size and scope to the maintenance requirements outlined in this Statement of Work. Experience must be specific to provision of laboratory instrument maintenance and shall include the following information for each contract or purchase order listed:a. Name of Contracting Organizationb. Total Contract Valuec. Description of Requirement d. Contract Period of Performance
Past Performance shall be evaluated for relevance to the current requirement.
Technical proposals will be evaluated using a summary adjectival rating in accordance with the following scale:
ExcellentThe proposal has exceptional merit and reflects an excellent approach which will clearly result in the superior attainment of all requirements and objectives. This clearly achievable approach includes several advantageous characteristics of substance, and very few disadvantages, which can be expected to result in outstanding performance. The risk of unsuccessful performance is very low as the proposal provides solutions which are unquestionably feasible and practical. These solutions are further considered very low risk in that they are exceptionally clear andprecise, fully supported, and demonstrate a clear understanding of the requirements. Risk Level: Very Low
GoodThe proposal demonstrates a sound approach which is expected to meet all requirements and objectives. This sound approach includes advantageous characteristics of substance, and few relatively minor disadvantages, which collectively can be expected to result in satisfactory performance. The risk of unsuccessful performance is low as the proposal contains solutions which are considered feasible and practical. These solutions are further considered to reflect low risk in that they are clear and precise, supported, and demonstrate an understanding of the requirements. Risk Level: Low
AcceptableThe proposal demonstrates an approach which is capable of meeting all requirements and objectives. The approach includes both advantageous and disadvantageous characteristics of substance, where the advantages are not outweighed by the disadvantages. Collectively, the advantages and disadvantages are likely to result in acceptable performance. The risk of unsuccessful performance is moderate, as the proposal solutions are generally feasible and practical. These solutions may also be considered to reflect moderate risk in that they may be somewhat clear and precise, partially supported, and/or demonstrate a general understanding of the requirements. Risk Level: Neutral
MarginalThe proposal demonstrates an approach which may not be capable of meeting all requirements and objectives. The approach has disadvantages of substance and advantages, which if they exist, are outweighed by the disadvantages. Collectively, the advantages and disadvantages present a low or questionable likelihood of resulting in satisfactory performance. The risk of unsuccessful performance is high as the proposal contains solutions which may not be feasible and practical. These solutions may also be considered to reflect high risk in that they lack clarity and precision, are generally unsupported, and/or do not demonstrate a complete understanding of the requirements. Risk Level: High
UnacceptableThe proposal demonstrates an approach which, based on a very high risk, will very likely not be capable of meeting all requirements and objectives. This approach has several disadvantages of substance, and advantages which, if they exist, are outweighed by disadvantages. Collectively, the advantages and disadvantages are unlikely to result in satisfactory performance. The risk of unsuccessful performance is very high as the proposal contains solutions which are not feasible and practical. The solutions may also be considered to reflect very high risk in that they lack any clarity or precision. Risk Level: Very High
APPLICABLE TERMS AND CONDITIONS INCORPORATED BY REFERENCEThe FAR clauses and provisions below shall apply to this solicitation.
1. All Offerors MUST be actively registered in the System for Award Management (SAM) www.sam.gov.
2. The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items (October 2016), applies to this acquisition.
3. A completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications - Commercial Items (October 2016), is required with any offer submitted. This requirement may be met by completion of the provision in the System for Award Management.
4. FAR Clause 52.212-4, Contract Terms and Conditions - Commercial Items (May 2015) is applicable to this acquisition.
5. FAR Clause 52.212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items (November 2016) apply to this acquisition. The following clauses shall be checked/included in this clause:
52.204-10, Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2015)52.209-6, Protecting the Government's Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment. (Oct 2015) (31 U.S.C. 6101 note).52.219-4, Notice of Price Evaluation Preference for HUBZone Small Business Concerns (OCT 2014) (if the offeror elects to waive the preference, it shall so indicate in its offer)52.219-28, Post Award Small Business Program Rerepresentation (Jul 2013) 52.222-3, Convict Labor (June 2003) 52.222-19, Child Labor-Cooperation with Authorities and Remedies (Feb 2016)52.222-21, Prohibition of Segregated Facilities (Apr 2015).52.222-26, Equal Opportunity (Sept 2016)52.222-36, Equal Opportunity for Workers with Disabilities (Jul 2014)52.222-50, Combating Trafficking in Persons (Mar 2015)52.222-53, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services-Requirements (May 2014)
52.223-18, Encouraging Contractor Policies to Ban Text Messaging While Driving (AUG 2011)52.225-13, Restrictions on Certain Foreign Purchases (June 2008)52.232-33, Payment by Electronic Funds Transfer-System for Award Management (Jul 2013)
6. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement.
In addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response.
CLOSING STATEMENTAll responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency. All responses must be received by the closing date of this announcement must reference solicitation number HHS-NIH-NIDA-SSSA-NOI-17-268.
Responses shall be submitted electronically to email@example.com. Fax responses will not be accepted. For information regarding this solicitation, contact Jermaine Duncan by email at firstname.lastname@example.org or by phone at (301) 827-7515.